logo
Plus   Neg
Share
Email

Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

Gilead Sciences Inc. (GILD) said Friday that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.

As per the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets.

Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.

Gilead said its antiviral portfolio includes among the most widely used medicines for the treatment of HIV, hepatitis B and hepatitis C, as well as influenza infection.

Separately, Novartis said that the Chinese National Medical Products Administration approved Gilenya for relapsing forms of multiple sclerosis for adults and children 10 years and older.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
US investment bank JPMorgan Chase & Co. reported Tuesday a profit for the third quarter that increased 8 percent from last year, driven by record revenues, partially offset by higher provision for credit losses and lower interest rates. Both earnings per share and revenues for the quarter topped analysts' expectations. While reporting financial results for the third quarter, Johnson & Johnson (JNJ) on Tuesday raised its earnings and sales forecast for the full year 2019. For fiscal 2019, the company now projects adjusted earnings in a range of $8.62 to $8.67 per share and adjusted operational earnings in a range... Uber Technologies Inc. (UBER) said Monday that it laid off about 350 employees across several different teams, as part of its final phase of layoffs of the process it began earlier this year.
Follow RTT
>